Pulmonary Cell News Volume 8.42 | Oct 31 2019

TOP STORY

Engineered Amphiphilic Peptides Enable Delivery of Proteins and CRISPR-Associated Nucleases to Airway Epithelia

Scientists achieved protein and SpCas9 or AsCas12a ribonucleoprotein delivery to cultured human well-differentiated airway epithelial cells and mouse lungs with engineered amphiphilic peptides. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

Cytokine Induction in Nipah Virus-Infected Primary Human and Porcine Bronchial Epithelial Cells

To elucidate the reasons for species-specific differences in Nipah virus (NiV) airway infections, investigators compared the cytokine responses as a first reaction to NiV in primary porcine and human bronchial epithelial cells. [J Infect Dis] Abstract

Transcriptomic Profile of Cystic Fibrosis Airway Epithelial Cells Undergoing Repair

Scientists collected RNA-seq data from well-differentiated primary cultures of bronchial human airway epithelial cells of cystic fibrosis (CF) and non-CF origins before and after mechanical wounding, exposed or not to flagellin. [Sci Data] Full Article

Osteopontin Expression in Small Airway Epithelium in COPD Is Dependent on Differentiation and Confined to Subsets of Cells

Researchers investigated the distribution of osteopontin-expressing cells in the airway epithelium of normal lung tissue and that from patients with chronic obstructive pulmonary disease (COPD). [Sci Rep] Full Article

Cigarette Smoke Affects the Onco-Suppressor DAB2IP Expression in Bronchial Epithelial Cells of COPD Patients

In ex vivo studies, the authors assessed enhancer of zeste homolog 2 (EZH2), histone H3 tri-methylation in lysine 27 and disabled homolog 2 interacting protein gene (DAB2IP) immunoreactivity in bronchial epithelial cells from COPD patients, smoker and control subjects. [Sci Rep] Full Article

LUNG CANCER

YTHDF1 Links Hypoxia Adaptation and Non-Small Cell Lung Cancer Progression

The authors showed that YTHDF1 deficiency inhibited non-small cell lung cancer cell proliferation and xenograft tumor formation through regulating the translational efficiency of CDK2, CDK4, and cyclin D1, and that YTHDF1 depletion restrained de novo lung adenocarcinomas progression. [Nat Commun] Full Article

WNT5B Exerts Oncogenic Effects and Is Negatively Regulated by miR-5587-3p in Lung Adenocarcinoma Progression

Silencing WNT5B suppresses the proliferation of lung adenocarcinoma (LAD) both in vitro and in vivo by interfering G1/S cell-cycle progression and modulating amino acid metabolism, revealing its remarkable oncogenic role in LAD. [Oncogene] Abstract

MicroRNA-421 Confers Paclitaxel Resistance by Binding to the KEAP1 3′UTR and Predicts Poor Survival in Non-Small Cell Lung Cancer

Researchers found that miR-421 suppresses kelch-like ECH-associated protein 1 (KEAP1) expression by targeting its 3′-untranslated region (3′UTR). A Q-PCR assay demonstrated that miR-421 was overexpressed in non-small cell lung cancer, especially in A549 cells. [Cell Death Dis] Full Article

MicroRNA‐147b Suppresses the Proliferation and Invasion of Non‐Small‐Cell Lung Cancer Cells through Downregulation of Wnt/β‐Catenin Signaling via Targeting of RPS15A

Investigators aimed to report the biological function and signaling pathways mediated by miR‐147b in non‐small‐cell lung cancer (NSCLC). They demonstrated that miR‐147b expression was significantly downregulated in NSCLC tissues and cell lines. [Clin Exp Pharmacol Physiol] Abstract

Subscribe to one of our other 19 science newsletters such as Cancer Stem Cell News & Human Immunology News.

Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer

The authors conducted a comprehensive review to categorize fusion events by the generation of EGFR tyrosine kinase inhibitors (TKIs), the specific receptor tyrosine kinase fusions and their fusion partners, the founder EGFR mutations, and their methods of detection. [Trends Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer

Telix Pharmaceuticals Limited announced that Telix and AusHealth have entered into a collaboration and technology licensing agreement for a novel Molecularly Targeted Radiation platform called APOMAB^® intended for the treatment of ovarian and lung cancers. [Telix Pharmaceuticals Limited (GlobeNewswire, Inc.)] Press Release

Laurent Pharmaceuticals Receives an Additional up to $3M Award from Cystic Fibrosis Foundation

Laurent Pharmaceuticals Inc. announced that it has reached an agreement to receive an additional funding of up to US$ 3 million from the US-based Cystic Fibrosis Foundation to further support its APPLAUD Phase II clinical study evaluating the company’s lead compound LAU-7b in adult patients with cystic fibrosis. [Laurent Pharmaceuticals Inc. (Business Wire, Inc.)] Press Release

A Powerful Tuberculosis Drug Gets a Deep Price Cut

A 66% price slash of a little used but powerful drug that prevents tuberculosis could help stave off the deadly lung disease in millions of people around the world. Sanofi announced it will sell the drug rifapentine at the steeply discounted price. The full course of preventive treatment with the drug will drop from $45 to $15. [ScienceInsider] Editorial

Swiss Authorities Probe Boehringer Ingelheim and Other Companies for Antitrust Practices

A Swiss government agency that last month opened an antitrust investigation into several drug makers and distributors has now disclosed the names of nearly a dozen companies that may have fixed the market for an ingredient used to make a treatment for stomach pain. [STAT News] Editorial

Increase in Academics Leaving the UK Since Brexit Vote

After the 2016 Brexit referendum, in which voters decided to have the UK leave the European Union (EU), the number of academics from EU countries leaving the United Kingdom for other university jobs increased by almost half, according to Times Higher Education. [The Scientist] Editorial

PhD-Turned-Policy Insider Takes Over World’s Largest Science Society

In January 2020, the 46-year-old structural biologist Sudip Parikh will become the new CEO of AAAS (which publishes Science) as the 171-year-old association pursues its mission to advance science and serve society. [ScienceInsider] Editorial

NEW Tissue Stem Cell Regulation by Autonomous and Non-Autonomous Mechanisms
July 12-17, 2020
Ventura, California, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow – Lung Cancer Epigenomics (Icahn School of Medicine at Mount Sinai)

Research Assistant – Pulmonary Research (Philipps University of Marburg)

Postdoctoral Research Fellow – Small Cell Lung Cancer (University Hospital of Cologne)

PhD Studentship – Small Cell Lung Cancer (Cancer Research UK Manchester Institute)

Postdoctoral Training Fellow – Machine Learning (Institute of Cancer Research)

Postdoctoral Research Fellow – Lung Development and Disease (Center for Regenerative Medicine)

Research Fellow – Lung Cancer (Dana-Farber Cancer Institute)

Faculty Position – Pulmonary and Critical Care Medicine (Mayo Clinic Comprehensive Cancer Center)

Research Scientist – Fibrosis (Gilead Sciences, Inc.)

Postdoctoral Positions – Sepsis and Pulmonary Injury (University of Maryland)

Postdoctoral Fellowship – Lung Epithelium (Boston University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.